RecruitingPhase 2NCT07027345
A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
Studying Autosomal dominant generalized epidermolysis bullosa simplex, severe form
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMendics, LLC
- Intervention
- 5% TolaSure Topical Gel(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2025 – 2026
Study locations (2)
- Stanford University School of Medicine, Dermatology Department, Palo Alto, California, United States
- NU Dermatolgy CTU, Chicago, Illinois, United States
Collaborators
Northwestern University Feinberg School of Medicine · Ann & Robert H Lurie Children's Hospital of Chicago · Stanford University · Lucile Packard Children's Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07027345 on ClinicalTrials.gov